Literature DB >> 10763947

What determines severity among patients with painful functional bowel disorders?

D A Drossman1, W E Whitehead, B B Toner, N Diamant, Y J Hu, S I Bangdiwala, H Jia.   

Abstract

OBJECTIVE: For patients with painful functional bowel disorders (FBD), physicians frequently make diagnostic and treatment decisions based on the severity of the pain reported; patients with severe painful complaints may receive extensive diagnostic tests and treatments. Therefore, it would be important to determine what clinical factors contribute to the judgment of severity among patients with FBD. The aim of this study was to identify the psychosocial, behavioral, and physiological (visceral sensitivity) factors that predicted severity in patients with moderate to severe FBD.
METHODS: Two hundred eleven female patients with moderate or severe FBD, as determined by the Functional Bowel Disorder Severity Index, entered a multicenter treatment trial at the University of North Carolina and the University of Toronto. Patients filled out diary cards and were given questionnaires and physiological testing (rectal sensitivity using barostat). Analysis of covariance and logistic regression adjusting for demographic factors were performed to determine which factors distinguished patients at study entry with moderate from those with severe FBD.
RESULTS: Patients with severe FBD were characterized by greater depression and psychological distress, poorer physical functioning and health-related quality of life, more maladaptive coping strategies, and greater health care utilization. There was a trend for patients with severe FBD to have lower rectal sensation thresholds. Regression analysis indicated that severity was best predicted by behavioral features: poorer daily physical function, difficulties related to eating, more phone calls to the physician, and more days in bed for GI symptoms.
CONCLUSIONS: We conclude that patient illness behaviors are best correlated with severity in FBD. The use of psychopharmacological agents (e.g., antidepressants) and psychological treatments to treat psychiatric comorbidity and to improve behavioral coping styles is recommended. Training to help medical physicians identify and respond to psychosocial and behavioral features of these conditions is likely to improve patient satisfaction with their care and the clinical outcome.

Entities:  

Mesh:

Year:  2000        PMID: 10763947     DOI: 10.1111/j.1572-0241.2000.01936.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  33 in total

1.  Structural and functional dichotomy of human midcingulate cortex.

Authors:  Brent A Vogt; Gail R Berger; Stuart W G Derbyshire
Journal:  Eur J Neurosci       Date:  2003-12       Impact factor: 3.386

Review 2.  Antidepressants for irritable bowel syndrome.

Authors:  R E Clouse
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

Review 3.  When is irritable bowel syndrome not irritable bowel syndrome? Diagnosis and treatment of chronic functional abdominal pain.

Authors:  Madhusudan Grover
Journal:  Curr Gastroenterol Rep       Date:  2012-08

4.  Altering the gastrointestinal flora in patients with functional bowel disorders: a way ahead?

Authors:  Magnus Simrén
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

5.  Brain imaging and its implications for studying centrally targeted treatments in irritable bowel syndrome: a primer for gastroenterologists.

Authors:  D A Drossman
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

6.  Treatment effects of partially hydrolyzed guar gum on symptoms and quality of life of patients with irritable bowel syndrome. A multicenter randomized open trial.

Authors:  Giancarlo Parisi; Enrico Bottona; Maurizio Carrara; Fabrizio Cardin; Alessandra Faedo; Dario Goldin; Marco Marino; Maurizio Pantalena; Gianni Tafner; Giorgio Verdianelli; Maurizio Zilli; Gioacchino Leandro
Journal:  Dig Dis Sci       Date:  2005-06       Impact factor: 3.199

Review 7.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

8.  Linaclotide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome.

Authors:  Ruchit Sood; Alexander C Ford
Journal:  Ther Adv Chronic Dis       Date:  2013-11       Impact factor: 5.091

9.  Treatment of Functional GI Disorders With Psychotropic Medicines: A Review of Evidence With a Practical Approach.

Authors:  Syed I M Thiwan; Douglas A Drossman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-09

Review 10.  New insights into the psychosocial aspects of irritable bowel syndrome.

Authors:  Richard Lea; Peter J Whorwell
Journal:  Curr Gastroenterol Rep       Date:  2003-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.